This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Squamous cell carcinoma of the head and neck (SCCHN)	Cyclin-dependent kinase inhibitor 2A (CDKN2A; INK4a; ARF)	Human tumor tissue analysis suggests that CDKN2A levels could help predict survival in a subset of SCCHN cancers associated with HPV infection. In 156 Danish SCCHN patients who received standard radiotherapy, patients with CDKN2A-positive tumors had significantly better overall survival than patients that had CDKN2A-negative tumors ($p=0.0003$). Next steps could include validating the CDKN2A biomarker in other patient populations.	Patent and licensing status unavailable	Lassen, P. <i>et al.</i> <i>J. Clin. Oncol.</i> ; published online March 16, 2009; doi:10.1200/JCO.2008.20.2853 Contact: Pernille Lassen, Aarhus University Hospital, Aarhus, Denmark e-mail: pernille@oncology.dk
<i>SciBX</i> 2(12); doi:10.1038/scibx.2009.489 Published online March 26, 2009				